Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-14 |
2024-06 |
-0.06 |
N/A |
N/A |
N/A |
2024-05-15 |
2024-03 |
-0.16 |
-0.18 |
-0.02 |
-12.50% |
2024-03-06 |
2023-12 |
-0.12 |
-0.24 |
-0.12 |
-100.00% |
2023-11-08 |
2023-09 |
-0.2 |
-0.2 |
N/A |
N/A |
2023-08-09 |
2023-06 |
-0.17 |
-0.21 |
-0.04 |
-23.53% |
2023-05-12 |
2023-03 |
-0.19 |
0.01 |
0.2 |
105.26% |
Date |
Firm |
Action |
From |
To |
2023-08-09 |
Barclays |
Upgrade |
Underweight |
Underweight |
2023-08-09 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-06-04 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-06-01 |
EF Hutton |
Upgrade |
|
Buy |
2023-05-25 |
EF Hutton |
Upgrade |
|
Buy |
2023-04-16 |
EF Hutton |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-05-31 |
ALLEVA LAWRENCE M |
Director |
0.00 |
Purchase |
2024-01-16 |
BERTRAND WILLIAM C JR |
Chief Operating Officer |
20.20K |
Sale |
2024-01-16 |
LUNGER JOHN |
Officer |
19.02K |
Sale |
2023-07-09 |
MENZEL GARRY E |
Director |
75.06K |
Sale |
2020-05-28 |
NOBLE JAMES J |
Director |
0.00 |
Sale |
2024-01-16 |
NORRY ELLIOT |
Officer |
19.26K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Matrix Capital Management |
38.97M |
36.05M |
25.20% |
2023-06-29 |
Baillie Gifford and Company |
17.18M |
15.89M |
11.11% |
2023-06-29 |
NEA Management Company, LLC |
17.08M |
15.80M |
11.04% |
2023-06-29 |
Baker Brothers Advisors, LLC |
10.97M |
10.15M |
7.09% |
2023-06-29 |
Pfm Health Sciences, Lp |
8.36M |
7.73M |
5.40% |
2023-06-29 |
Long Focus Capital Management, LLC |
7.81M |
7.23M |
5.05% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-07-30 |
Old Westbury Small & Mid Cap Strategies Fund |
2.40M |
2.26M |
1.55% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
843.43K |
658.04K |
0.55% |
2023-08-30 |
SPDR Portfolio Developed World ex-US ETF |
219.05K |
170.90K |
0.14% |
2023-06-29 |
Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF |
150.00K |
138.75K |
0.10% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
105.91K |
108.03K |
0.07% |
2023-06-29 |
Fidelity Small Cap Enhanced Index Fund |
99.82K |
92.34K |
0.06% |